# VM Discovery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vm-discovery

- Industry: Biotechnology
- Headquarters: Fremont, US
- Website: www.vmdiscovery.com
- Total disclosed funding: $11M
- Latest round: Series D (Jul 11, 2014)
- Investors on record: 2

## About

VM Discovery Inc. specializes in multivariate drug design, leveraging advanced computational methods to develop precision medicines, particularly targeting unmet medical needs in the pharmaceutical industry.Founded in 2001 in Fremont, US, VM Discovery Inc. operates primarily in the drug discovery sector, focusing on the optimization of drug candidates. The company has undergone successful rounds of funding, with the most recent being a Series D round in July 2014, raising USD 7.87 mn from Amkey Ventures and others. It has completed a total of six deals to date and is currently valued at USD 36.54 mn. The CEO, Jay Wu, has a background in founding and guiding other ventures in the biotechnology field.VMOptimizer is a sophisticated multivariate drug design platform dedicated to the development of precision medicines, especially those with first-in-class potential. This platform utilizes advanced computational methods to optimize drug candidates according to their unique properties, thereby addressing unmet medical needs across various therapeutic areas. By integrating robust data analytics with machine learning algorithms, VMOptimizer enhances the efficiency and efficacy of drug discovery processes for pharmaceutical companies, particularly in North America and Europe, where there is a growing demand for personalized medicine.VMOptimizer's revenue model is built around strategic partnerships and licensing agreements with pharmaceutical companies. Clients access the platform's advanced drug design capabilities through these collaborations, which typically involve upfront fees and milestone payments based on the successful development and commercialization of drug candidates. The company may also employ tiered subscription plans tailored to the varying needs of both large pharmaceutical firms and smaller biotech companies, ensuring flexible pricing structures within the pharmaceutical landscape.VM Discovery Inc. aims to launch new products designed to enhance its drug design capabilities, with specific timelines yet to be announced. The company is also looking to expand into additional markets beyond its current focus in North America and Europe, although specific regions have not been disclosed. The recent Series D financing of USD 7.87 mn will be utilized to support these initiatives, leveraging the funds for product development and market expansion efforts, as outlined in the rationale for this funding.

## Funding rounds

- Series D, Jul 11, 2014, $7.9M — Amkey Ventures
- Series C, Dec 18, 2006, $0.8M — Amkey Ventures
- Series B, Aug 13, 2006, $0.1M — Amkey Ventures
- Series B, Dec 19, 2005, $1M — ONSET Ventures, Amkey Ventures
- Series A, Sep 29, 2004, $0.1M — ONSET Ventures, Amkey Ventures
- Series A, May 30, 2003, $0.7M — ONSET Ventures, Amkey Ventures

## Investors

- ONSET Ventures (https://capitalatlas.ai/funds/onset-ventures) — Series A, Series B
- Amkey Ventures (https://capitalatlas.ai/funds/amkey-ventures) — Series A, Series B, Series C, Series D